Trial intelligence / Profile preview

Advagraf standard regimen versus lower-start slower-taper regimen in de novo renal transplant recipients

2013-001770-19Phase 3Completed

Sponsor: Technische Universität Dresden
Start: May 2014
Modality: RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 3, randomised, open-label trial of tacrolimus in kidney transplant immunosuppression (2 arms), sponsored by Technische Universität Dresden. Primary endpoints: Primary combined endpoint and Biopsy-proven rejection of Banff class Ia or higher and/or graft loss and/or patient death. Started May 2014; status: completed.

Drugs

tacrolimus

Conditions

kidney transplant immunosuppression

Beyond the preview

Go deeper on 2013-001770-19.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2013-001770-19.